Harmony Biosciences Holdings Executive Compensation (FY25)
HRMY · Executive and director compensation, fiscal 2025 only
The Harmony Biosciences Holdings brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 7, 2026Latest filing (8-K): May 14, 2026
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
166 figures on this page: 164 cited to the filing that reported them, 2 calculated from figures it prints. See the citations
Frequently asked questions
Answers drawn from the data on this page.
Who is Harmony Biosciences Holdings' chief executive and what were they paid?
Jeffrey Dayno, President and Chief Executive Officer, received $7,899,535 in total compensation for fiscal 2025.
What was Harmony Biosciences Holdings' say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 71.8% of votes cast for or against in favor at the meeting held May 14, 2026.
Which companies are in Harmony Biosciences Holdings' peer group?
Companies named in the disclosed peer group include Acadia, Alkermes, Axsome, Intra-Cellular and Ionis, among others.
What is Harmony Biosciences Holdings' chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 26:1, against median employee compensation of $303,481.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Jeffrey Dayno President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Adam Zaeske Executive Vice President and Chief Commercial Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Sandip Kapadia Executive Vice President, Chief Financial Officer and Chief Administrative Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Jeffrey Dierks Former Executive Vice President and Chief Commercial Officer Departed during or after this year | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
Kumar Budur Executive Vice President and Chief Medical and Scientific Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Andrew Serafin Executive Vice President and Chief Strategy Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Adam Zaeske | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Adam Zaeske | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Andrew Serafin | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Andrew Serafin | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Jeffrey Dierks | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Jeffrey Dierks | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Jeffrey M. Dayno | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Jeffrey M. Dayno | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Kumar Budur | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Kumar Budur | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Sandip Kapadia | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Sandip Kapadia | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Andrew Serafin | Option | ◇ | — | ◇ | 1/25/35 |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/24/34 | |
| Kumar Budur | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 3/21/32 | |
| Option | ◇ | — | ◇ | 5/1/34 | |
| Option | ◇ | — | ◇ | 1/25/35 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/24/34 | |
| RSU | ◇ | ◇ | — | — | |
| Adam Zaeske | RSU | ◇ | ◇ | — | — |
| Jeffrey Dayno | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 5/25/33 | |
| Option | ◇ | — | ◇ | 1/24/34 | |
| Option | ◇ | — | ◇ | 1/25/35 | |
| RSU | ◇ | ◇ | — | — | |
| Sandip Kapadia | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 1/24/34 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/25/35 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Ron Philip | ◇ | — | ◇ | — | — | — | ◇ |
Gary Sender | ◇ | — | ◇ | — | — | — | ◇ |
Antonio Gracias | ◇ | — | ◇ | — | — | — | ◇ |
R. Mark Graf | ◇ | — | ◇ | — | — | — | ◇ |
Juan A. Sabater | ◇ | — | ◇ | — | — | — | ◇ |
Peter Anastasiou | ◇ | — | ◇ | — | — | — | ◇ |
Linda Szyper | ◇ | — | ◇ | — | — | — | ◇ |
Jeffrey S. Aronin Board chair | ◇ | — | — | — | — | — | ◇ |
Jeffrey M. Dayno, Andreas Wicki, Troy Ignelzi and Geno Germano served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Acadia AKR
- Alkermes ALKS
- Axsome AXSM
- Intra-Cellular ITCI
- Ionis IONS
- Jazz Pharmaceuticals JAZZ
- Neurocrine Biosciences NBIX
- Sage Therapeutics SAGE
- Supernus SUPN
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | May 14, 2026 | = | ◇ | ◇ | ◇ |
| 2022 | May 25, 2023 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Harmony Biosciences Holdings disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Harmony Biosciences Holdings sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
166 figures on this page: 164 cited to the filing that reported them, 2 calculated from figures it prints.
164 cited to the filing
2 calculated from the filing
Documents cited
- 0001104659-26-061237
- 0001104659-26-039449CEO Pay Ratio · Director Compensation · Director Compensation Table · Grants of Plan-Based Awards · and 2 more sections
- 0001558370-23-010532
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Harmony Biosciences Holdings executive compensation, FY2025.” https://intel.velarion.ai/comp/HRMY (accessed 2026).
Short form: data: Velarion
The Harmony Biosciences Holdings brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Harmony Biosciences Holdings and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Harmony Biosciences Holdings discloses
The companies named in HRMY's own disclosed peer group.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}